ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
When Testosterone Is Not Enough
Use of the CNS Agent Bremelanotide (PT-141) in Men with Sexual Dysfunction
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 275944" data-attributes="member: 13851"><p>[URL unfurl="true"]https://academic.oup.com/jsm/article/21/Supplement_1/qdae001.217/7600941[/URL]</p><p></p><p></p><p><strong>Abstract</strong></p><p><strong></strong></p><p><strong>Introduction</strong></p><p></p><p><em><strong>Bremelanotide is a centrally acting, cyclic heptapeptide analog of the neuropeptide α-melanocyte-stimulating hormone with elevated affinity for the melanocortin-4 receptor. Bremelanotide modulates dopaminergic pathways involved in sexual desire and arousal. </strong>In an fMRI study, compared to placebo, bremelanotide was shown to improve connectivity between the amygdala and the insula during visual sexual stimulation, improve sexual brain processing, enhance cerebellar and supplementary motor area activity, and deactivate the secondary somatosensory cortex. <strong>Bremelanotide 1.75 mg/0.3 ml (Vyleesi®) is subcutaneously delivered by a single-use auto-injector which has been shown to result in increased genital blood flow within hours of administration in both men and women. </strong>While phase 2 studies were performed in men with erectile dysfunction (ED), bremelanotide is currently FDA-approved as an on-demand treatment for premenopausal women with generalized, acquired hypoactive sexual desire disorder (HSDD).<strong> Since its availability in September 2019, providers in our facility have been prescribing bremelanotide to premenopausal women, but off-label to postmenopausal women, and to men diagnosed with ED and other types of sexual dysfunction after undergoing a biopsychosocial evaluation.</strong></em></p><p></p><p></p><p><strong>Objective</strong></p><p></p><p><em>To better understand the use at our sexual medicine clinic of bremelanotide in men, <strong>we analyzed on and off-label prescribing patterns and refill rates over a 46-month period in both our male and female patients with various sexual dysfunctions.</strong></em></p><p></p><p></p><p><strong>Methods</strong></p><p></p><p><em>Bremelanotide prescription dispensing data specific to our sexual medicine facility during the period of September 2019 (inception) through June 30, 2023, was compiled. <strong>The analysis included the breakdown of prescription dispenses for men, premenopausal women (categorized by age 18-50), and postmenopausal women (categorized by age >50), with further analysis regarding refills and refill rates.</strong></em></p><p></p><p></p><p><strong>Results</strong></p><p><em>Over the 46-month period, bremelanotide has been dispensed for various sexual dysfunctions: <strong>76 times to premenopausal women, 104 times to postmenopausal women, and 444 times to men in our clinic.</strong> For premenopausal women, 29% of these dispenses were refills, for postmenopausal women, 52% of these dispenses were refills, and for men, 65% of these dispenses were refills. <strong>Over the last 18 months (January 1, 2022, through June 30, 2023), refill rates have been 47% for premenopausal women (n = 30), 52% for postmenopausal women (n = 29), and 73% for men (n = 219).</strong></em></p><p></p><p></p><p><strong>Conclusions</strong></p><p><strong></strong></p><p><strong><em>The refill rate and prescribing practices of any medication reflect, in part, the safety and efficacy of the treatment in a real-world setting. We observed increasing refill rates of bremelanotide in all patients. <u>Of note, our male patients have particularly high refill rates, implying that bremelanotide, a centrally acting agent, can be used on demand to successfully treat a variety of sexual dysfunctions</u>.</em></strong></p></blockquote><p></p>
[QUOTE="madman, post: 275944, member: 13851"] [URL unfurl="true"]https://academic.oup.com/jsm/article/21/Supplement_1/qdae001.217/7600941[/URL] [B]Abstract Introduction[/B] [I][B]Bremelanotide is a centrally acting, cyclic heptapeptide analog of the neuropeptide α-melanocyte-stimulating hormone with elevated affinity for the melanocortin-4 receptor. Bremelanotide modulates dopaminergic pathways involved in sexual desire and arousal. [/B]In an fMRI study, compared to placebo, bremelanotide was shown to improve connectivity between the amygdala and the insula during visual sexual stimulation, improve sexual brain processing, enhance cerebellar and supplementary motor area activity, and deactivate the secondary somatosensory cortex. [B]Bremelanotide 1.75 mg/0.3 ml (Vyleesi®) is subcutaneously delivered by a single-use auto-injector which has been shown to result in increased genital blood flow within hours of administration in both men and women. [/B]While phase 2 studies were performed in men with erectile dysfunction (ED), bremelanotide is currently FDA-approved as an on-demand treatment for premenopausal women with generalized, acquired hypoactive sexual desire disorder (HSDD).[B] Since its availability in September 2019, providers in our facility have been prescribing bremelanotide to premenopausal women, but off-label to postmenopausal women, and to men diagnosed with ED and other types of sexual dysfunction after undergoing a biopsychosocial evaluation.[/B][/I] [B]Objective[/B] [I]To better understand the use at our sexual medicine clinic of bremelanotide in men, [B]we analyzed on and off-label prescribing patterns and refill rates over a 46-month period in both our male and female patients with various sexual dysfunctions.[/B][/I] [B]Methods[/B] [I]Bremelanotide prescription dispensing data specific to our sexual medicine facility during the period of September 2019 (inception) through June 30, 2023, was compiled. [B]The analysis included the breakdown of prescription dispenses for men, premenopausal women (categorized by age 18-50), and postmenopausal women (categorized by age >50), with further analysis regarding refills and refill rates.[/B][/I] [B]Results[/B] [I]Over the 46-month period, bremelanotide has been dispensed for various sexual dysfunctions: [B]76 times to premenopausal women, 104 times to postmenopausal women, and 444 times to men in our clinic.[/B] For premenopausal women, 29% of these dispenses were refills, for postmenopausal women, 52% of these dispenses were refills, and for men, 65% of these dispenses were refills. [B]Over the last 18 months (January 1, 2022, through June 30, 2023), refill rates have been 47% for premenopausal women (n = 30), 52% for postmenopausal women (n = 29), and 73% for men (n = 219).[/B][/I] [B]Conclusions [I]The refill rate and prescribing practices of any medication reflect, in part, the safety and efficacy of the treatment in a real-world setting. We observed increasing refill rates of bremelanotide in all patients. [U]Of note, our male patients have particularly high refill rates, implying that bremelanotide, a centrally acting agent, can be used on demand to successfully treat a variety of sexual dysfunctions[/U].[/I][/B] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
When Testosterone Is Not Enough
Use of the CNS Agent Bremelanotide (PT-141) in Men with Sexual Dysfunction
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top